ResMed Inc.

ResMed Inc.

238.19
USD
-1.34
(-0.56%)
10.98EPS
20.08P/E
31.10BMarket Cap
Jan 28Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
10.99
11.95
13.11
14.62
16.39
18.21
20.49
22
24.5
28.77
31.87
35.08
38.85
39.61
Basic EPS, GAAP
2.44
2.51
2.51
2.42
2.21
2.83
4.31
3.27
5.34
6.12
6.94
9.55
10.47
11.01
Free Cash Flow per Basic Share
2.19
2.22
3.42
2.42
3.04
2.67
4.82
4.27
1.34
3.81
8.75
11.25
11.19
10.98
Dividend per Share
1
1.12
1.2
1.32
1.4
1.48
1.56
1.56
1.68
1.76
1.92
2.12
2.4
2.47
Book Value per Share
12.53
11.3
12.05
13.79
14.43
14.42
17.23
19.81
22.95
28.08
33.11
40.77
45.66
42.29
Tangible Book Value per Share
10.15
9.08
2.39
4.46
5.43
-2.13
1.09
3.88
7.37
5.49
10.46
16.78
22.35
18.46
Basic Weighted Avg Shares
141
140
140
141
143
143
144
145
146
147
147
147
146
145
Sales/Revenue/Turnover
1,555
1,679
1,839
2,067
2,340
2,607
2,957
3,197
3,578
4,223
4,685
5,146
5,653
5,733
Operating Margin (%)
26.46
24.38
23.7
22.1
23.94
24.4
27.36
28.54
28.01
27.28
29.54
32.75
33.76
33.13
Depreciation Expense
73
73
87
112
120
151
181
192
194
198
216
236
244
238
Net Income, GAAP
345
353
352
342
316
405
622
475
779
898
1,021
1,401
1,523
1,593
Effective Tax Rate (%)
19.9
19.05
19.83
18.26
39.46
22.02
15.2
46.3
18.85
18.53
19.28
16.5
20.64
20.81
Profit Margin (%)
22.2
21.02
19.17
16.56
13.49
15.52
21.02
14.84
21.78
21.25
21.79
27.22
26.94
27.79
Working Capital
1,287
1,141
782
1,284
554
589
921
663
1,242
1,609
1,447
2,486
2,930
2,185
LT Debt
301
301
873
1,079
270
1,259
1,266
758
886
1,548
839
811
537
419
Total Equity
1,758
1,587
1,695
1,960
2,059
2,072
2,497
2,886
3,361
4,130
4,864
5,968
6,585
5,948
Return on Invested Capital (%)
16.13
16.63
14.28
11.63
11.76
15.26
18.87
12.38
19.54
18.25
18.32
21.96
20.67
21.78
Return on Capital (%)
17.64
18.12
15.2
12.37
12.37
15.23
18.37
13.04
20.04
18.75
18.48
22.31
21.41
23.61
Return on Common Equity (%)
20.5
21.1
21.47
18.73
15.7
19.59
27.21
17.63
24.96
23.96
22.7
25.86
24.27
26.4

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'27
ST Debt
289
289
192
LT Borrowings
404
399
250
LT Finance Leases
150
137
169
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
145
144
141
Market Capitalization
32,559
28,109
31,095

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'27
Total Current Assets
4,064
4,325
3,509
Cash, Cash Equivalents & STI
1,661
1,469
1,011
Accounts Receivable, Net
999
1,036
972
Inventories
912
946
1,021
Total Current Liabilities
1,351
1,395
1,324
Payables & Accruals
883
885
961
ST Debt
289
289
192
Deferred Revenue
179
163
172

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.76%
18.03%
10.35%
Free Cash Flow
33.25%
55.02%
-1.35%
Net Income, GAAP
18.66%
27.82%
8.75%
Sales/Revenue/Turnover
11.92%
12.12%
9.85%
Total Cash Common Dividend
7.64%
9.08%
12.47%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1,225
1,282
1,292
1,348
5,146
2026
1,336
1,423
1,431
1,464
5,653
2027
1,415
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.12
2.35
2.49
2.59
9.55
2026
2.38
2.69
2.74
2.65
10.47
2027
2.93
- -
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.53
0.53
0.53
0.53
2.12
2026
0.6
0.6
0.6
0.6
2.4
2027
0.66
- -
- -
- -
- -

Company Description

CEO
Michael J. Farrell
Full Time Employees
11,370
Sector
Health technology
Industry
Medical specialties
Address
9001 Spectrum Center Boulevard San Diego CA United States 92123
IPO Date
Jun 1, 1995
Website
resmed.com
Business
ResMed Inc. (NYSE: RMD; ASX: RMD) develops, manufactures, distributes and markets cloud-connected medical devices, digital health technologies and software platforms that diagnose, treat and manage sleep-disordered breathing, chronic obstructive pulmonary disease (COPD), respiratory insufficiency and other chronic diseases. The company offers continuous positive airway pressure (CPAP) and automatic positive airway pressure (APAP) devices including the AirSense and Air11 series; masks and accessories such as the AirFit, AirTouch N30i and F30i fabric-based platforms; ventilators like the Lumis series for non-invasive support; humidifiers including HumidCare; portable options such as AirMini; and software solutions encompassing myAir for patient self-monitoring, AirView for remote clinician oversight, and SaaS platforms for out-of-hospital care providers including residential care management tools. It operates through two primary segments: Sleep and Respiratory Care, addressing obstructive sleep apnea, central sleep apnea, overlap syndrome, obesity hypoventilation and neuromuscular diseases; and Software as a Service (SaaS), supporting healthcare professionals with data-driven platforms. ResMed serves patients, clinicians, sleep labs, homecare providers and health systems in over 140 countries, with key growth markets in the United States, Canada, Latin America, Europe, China, South Korea, India, Brazil and Eastern Europe. Founded in 1989 by Dr. Peter Farrell in Sydney, Australia, to commercialize CPAP technology, the company is headquartered in San Diego, California, and employs approximately 10,600 people. Recent developments include the May 2025 acquisition of VirtuOx, a leading independent diagnostic testing facility for at-home sleep, respiratory and cardiac testing, which operates as a wholly owned subsidiary to streamline diagnostics, enhance virtual care coordination and expand into adjacent areas like insomnia; launches of new AirTouch F30i mask variants including the comfort edition in Australia and clear edition in the U.S.; strategic U.S. manufacturing and distribution expansion in Indianapolis; and a board leadership change with director Richard Sulpizio departing following the 2025 annual stockholders' meeting.

Company News

  • SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of ResMed Inc. (NYSE: RMD).

  • ResMed (NYSE:RMD) vs. Terumo (OTCMKTS:TRUMY) Financial Comparison

  • Don't Lose Sleep Over GLP-1s: Why ResMed Is a Bargain

  • Top 10 High Growth Dividend Stocks For November 2026

  • ResMed: 3 Key Takeaways for Long-Term Investors

  • ResMed (RMD) Reports Q1 Earnings: What Key Metrics Have to Say

  • RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs

  • What ResMed (RMD) Said on Its Q1 Earnings Call

  • ResMed Inc. (RMD) Q1 2027 Earnings Call Transcript

  • ResMed (RMD) Beats Q1 Earnings and Revenue Estimates

  • ResMed Q1 2027 Earnings Call Transcript

  • Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027

  • Here's Why ResMed (RMD) is a Strong Growth Stock

  • Unlocking Q1 Potential of ResMed (RMD): Exploring Wall Street Estimates for Key Metrics

  • Why Investors Need to Take Advantage of These 2 Medical Stocks Now

  • Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?

  • ResMed Set to Report Q1 Earnings: What's in the Cards for the Stock?

  • ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

  • Resmed Launches AirTouch™ F40 Full Face Fabric CPAP Mask in the U.S.

  • Top 50 High-Quality Dividend Growth Stocks For October 2026